Fiscal Period | 2025 | 2024 | 2023 | 2022 |
---|---|---|---|---|
Period End Date | Mar 25 | Mar 24 | Mar 23 | Mar 22 |
Total Operating Expense | 14.04 | 5.70 | 24.13 | 15.32 |
Other Net | 2.41 | 2.26 | 6.02 | 0.00 |
Diluted Weighted Average Shares | 2.21 | 1.36 | 1.36 | 1.36 |
Depreciation/ Amortization | 0.05 | 0.01 | 0.00 | 0.00 |
Operating Income | -2.29 | -1.65 | -3.74 | 1.46 |
Net Income | 0.09 | 0.45 | 1.62 | 1.09 |
Income Availableto Com Excl Extra Ord | 0.09 | 0.45 | 1.62 | 1.09 |
Net Income Before Taxes | 0.13 | 0.61 | 2.28 | 1.46 |
Other Operating Expenses Total | 0.84 | 4.06 | 4.59 | 1.37 |
Net Income After Taxes | 0.09 | 0.45 | 1.62 | 1.09 |
Income Availableto Com Incl Extra Ord | 0.09 | 0.45 | 1.62 | 1.09 |
Costof Revenue Total | 13.08 | 1.56 | 19.33 | 13.77 |
Gross Profit | -1.32 | 2.50 | 1.06 | 3.01 |
Interest Inc( Exp) Net- Non- Op Total | 0.00 | - | - | 0.00 |
Diluted Net Income | 0.09 | 0.45 | 1.62 | 1.09 |
Provisionfor Income Taxes | 0.04 | 0.16 | 0.67 | 0.37 |
period Type | - | - | - | - |
Net Income Before Extra Items | 0.09 | 0.45 | 1.62 | 1.09 |
Total Revenue | 11.76 | 4.05 | 20.39 | 16.78 |
period Length | 12.00 | 12.00 | 12.00 | 12.00 |
Revenue | 11.76 | 4.05 | 20.39 | 16.78 |
Selling/ General/ Admin Expenses Total | 0.07 | 0.08 | 0.20 | 0.18 |
Diluted Normalized EPS | 0.04 | 0.33 | 1.19 | 0.80 |
Diluted EPS Excluding Extra Ord Items | 0.04 | 0.33 | 1.19 | 0.80 |
Total Adjustmentsto Net Income | - | - | - | 0.00 |
DPS- Common Stock Primary Issue | - | - | - | 0.00 |
Evoq Remedies Dividend Evoq Remedies Bonus Evoq Remedies News Evoq Remedies AGM Evoq Remedies Rights Evoq Remedies Splits Evoq Remedies Board Meetings Evoq Remedies Key Metrics Evoq Remedies Shareholdings Evoq Remedies Balance Sheet Evoq Remedies Cashflow Evoq Remedies Q1 Results Evoq Remedies Q2 Results Evoq Remedies Q3 Results Evoq Remedies Q4 Results
Top GainersTop LosersIndian IndicesBSE Active StocksNSE Active Stocks